BLOG

For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

The company, which is working on drugs based on antisense oligonucleotides to treat genetic conditions, announced a reverse merger with Ohr Pharmaceutical on Jan. 3, which would allow its stock to trade publicly.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}